Boston Sales General And Administrative To Revenue from 2010 to 2024

BSX Stock  USD 91.50  1.33  1.47%   
Boston Scientific Sales General And Administrative To Revenue yearly trend continues to be fairly stable with very little volatility. Sales General And Administrative To Revenue will likely drop to 0.29 in 2024. During the period from 2010 to 2024, Boston Scientific Sales General And Administrative To Revenue regression line of annual values had r-squared of  0.13 and arithmetic mean of  0.36. View All Fundamentals
 
Sales General And Administrative To Revenue  
First Reported
2010-12-31
Previous Quarter
0.33
Current Value
0.29
Quarterly Volatility
0.02459326
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Boston Scientific financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boston Scientific's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 B, Interest Expense of 193.9 M or Selling General Administrative of 5.2 B, as well as many indicators such as Price To Sales Ratio of 4.58, Dividend Yield of 3.0E-4 or PTB Ratio of 5.87. Boston financial statements analysis is a perfect complement when working with Boston Scientific Valuation or Volatility modules.
  
Check out the analysis of Boston Scientific Correlation against competitors.

Latest Boston Scientific's Sales General And Administrative To Revenue Growth Pattern

Below is the plot of the Sales General And Administrative To Revenue of Boston Scientific Corp over the last few years. It is Boston Scientific's Sales General And Administrative To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boston Scientific's overall financial position and show how it may be relating to other accounts over time.
Sales General And Administrative To Revenue10 Years Trend
Slightly volatile
   Sales General And Administrative To Revenue   
       Timeline  

Boston Sales General And Administrative To Revenue Regression Statistics

Arithmetic Mean0.36
Geometric Mean0.36
Coefficient Of Variation6.88
Mean Deviation0.02
Median0.36
Standard Deviation0.02
Sample Variance0.0006
Range0.1032
R-Value(0.36)
Mean Square Error0.0006
R-Squared0.13
Significance0.18
Slope(0)
Total Sum of Squares0.01

Boston Sales General And Administrative To Revenue History

2024 0.29
2023 0.33
2017 0.36
2015 0.38
2014 0.39
2013 0.37

About Boston Scientific Financial Statements

Boston Scientific investors use historical fundamental indicators, such as Boston Scientific's Sales General And Administrative To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Boston Scientific. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Sales General And Administrative To Revenue 0.33  0.29 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.